Microfluidic Drug Screening Platform for Intraperitoneal Chemotherapy Simulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug screening methods for hyperthermic intraperitoneal chemotherapy are inefficient due to reliance on manual selection based on doctor experience, leading to variable treatment outcomes and resource wastage, as they fail to accurately simulate the temperature-controlled intraperitoneal environment.
Innovation Solution
A microfluidic drug screening platform utilizing dielectrophoresis, three-dimensional cell culture, and heating control systems to automate drug combination and mixing, enabling precise simulation of intraperitoneal thermochemotherapy environments for cancer cell culture and drug testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If manual drug screening methods are used based on doctor experience, then the process is simple to operate, but the screening efficiency is low and treatment delays occur
Solution Approach 1:
The microfluidic chip automatically performs drug combination screening through integrated channels that mix multiple drugs and perfuse them to cancer cells without manual intervention. The system self-regulates fluid flow and drug combination generation, eliminating the need for manual operation while maintaining simplicity.
Solution Approach 2:
The patent replaces manual mechanical drug mixing and perfusion operations with automated microfluidic flow control. The microfluidic channels use pressure-driven flow and geometric design to automatically combine drugs and deliver them to cells, substituting manual mechanical operations with automated fluid dynamics-based systems.
2Device complexity
If conventional culture plates are used for drug screening, then the device structure is simple, but the temperature control capability is insufficient for simulating intraperitoneal thermochemotherapy environment
Solution Approach 1:
The patent merges the culture plate with a heating system and microfluidic drug delivery channels into an integrated platform. The culture plate structure is combined with temperature control components and drug perfusion channels, allowing simultaneous temperature control and drug screening in a single device.
Solution Approach 2:
The microfluidic chip serves multiple functions: it acts as a culture vessel, a drug mixing device, a temperature-controlled environment, and a perfusion system. This multi-functional design allows the single device to perform drug screening, temperature control, and fluid delivery without requiring separate equipment.
3Measurement precision
If multiple drug combinations are tested manually, then each drug can be evaluated individually, but the screening process is time-consuming and resource-intensive
Solution Approach 1:
The patent segments the drug screening process into multiple parallel microfluidic channels, each capable of testing different drug combinations simultaneously. The microfluidic chip is divided into separate flow paths that can process multiple drug permutations at the same time, maintaining individual evaluation accuracy while enabling parallel testing.
Solution Approach 2:
The microfluidic system enables continuous perfusion of multiple drug combinations through the cancer cell culture without interruption. Drugs are continuously delivered and mixed in real-time, allowing uninterrupted screening of multiple combinations simultaneously, eliminating the need to sequentially test each drug combination.
4Productivity
If automatic drug combination systems are implemented, then screening efficiency improves, but the device complexity increases
Solution Approach 1:
The patent uses pressure-driven microfluidic flow control to automate drug combination delivery. By applying pressure differentials through the microfluidic channels, the system automatically perfuses drugs and culture medium without requiring complex mechanical pumps or valves, achieving automation through simple hydraulic principles.
Solution Approach 2:
The microfluidic chip uses geometric design parameters (channel width, height, and configuration) to control fluid flow and drug mixing ratios. By changing the physical dimensions and geometry of the channels, the system automatically adjusts drug combination ratios without requiring complex control systems or programming.
Data Source
AI summary
A drug screening platform simulating hyperthermic intraperitoneal chemotherapy including a dielectrophoresis system, a microfluidic chip and a heating system is disclosed. The dielectrophoresis system is used to provide a dielectrophoresis force. The microfluidic chip includes a cell culture array and observation module and a drug mixing module. The cell culture array and observation module are used to arrange the cells into a three-dimensional structure through the dielectrophoresis force to construct a three-dimensional tumor microenvironment. The drug mixing module is coupled to the cell culture array and observation module and used to automatically split and mix the inputted drugs and output the drug combinations into the cell culture array and observation module. The heating system is used for real-time temperature sensing and heating control of the drug combinations on the microfluidic chip to simulate high-temperature drug environment when performing hyperthermic intraperitoneal chemotherapy on the three-dimensional tumor microenvironment.